
Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

Jayakrishna Ambati, MD, is director of the Center for Advanced Vision Science and the DuPont Guerry III professor of ophthalmology at the University of Virginia in Charlottesville and founder of Inflammasome Therapeutics.

Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.